Winton Group LTD Immunovant, Inc. Transaction History

Winton Group LTD

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$25.1 - $31.61 $518,942 - $653,536	20,675 New	20,675 $545,000
Q4 2021 Feb 10, 2022	SELL	$7.33 - $9.32 $348,724 - $443,399	-47,575 Closed	0 $0
Q3 2021 Oct 28, 2021	SELL	$7.01 - $11.37 $21,780 - $35,326	-3,107 Reduced 6.13%	47,575 $413,000
Q2 2021 Aug 10, 2021	BUY	$9.4 - $16.85 $246,054 - $441,065	26,176 Added 106.81%	50,682 $536,000
Q1 2021 Jul 21, 2021	BUY	$13.08 - $49.6 $231,777 - $878,912	17,720 Added 261.13%	24,506 $393,000
Q4 2020 Feb 12, 2021	BUY	$36.36 - $52.71 $246,738 - $357,690	6,786 New	6,786 $313,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.